April 20, 2015
The Ministry of Health, Labor and Welfare has granted priority review status to AbbVie’s investigational direct-acting oral antiviral agent containing ombitasvir, paritaprevir, and ritonavir, the company said. The once-daily and interferon and ribavirin-free drug was filed for approval in Japan...read more